Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
US off-patent industry association the AAM has blasted as unconstitutional a groundbreaking California law banning so-called ‘pay-for-delay’ deals under which brand companies pay rivals to keep generics off the market.
Indian credit rating agency ICRA has forecast that the country’s pharmaceutical industry will remain on a steady 11%-13% growth path this fiscal year, underpinned by healthy domestic demand, new launches and market share gains.
India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”
A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.
Generics giant Mylan, which has a large chunk of its manufacturing operations in India, has said it will invest $1bn over the next five to six years in the country, maintaining the spending pace the company has established over the last few years.